To access the webcast or the replay.

A live webcast the conference call on the company website are available and will be archived for 30 days. To access the webcast or the replay, go to the link ‘Investor Relations’and click on ‘Webcasts and Data. ‘.

After 24 months the overall survival was 10, 6 percent in TNFerade and SOC arm versus 11.3 percent in the SOC arm. The median survival was 9.9 months in both arms of the study. ‘Successfully passing this milestone in the PACT study is an important step in the clinical development of TNFerade,’said Mark continued: ‘, Senior Vice President of Product Development at GenVec. Thornton continued: ‘We believe that these data are encouraging and justify moving ahead with the study, the continuation of the trial will allow the data to mature and for future analyzes we currently estimate we will need the required number of events. Next next behavior analysis of data in the PACT study in late 2009.A child can not be of genetic variation Such both parents. This brand new or new mutations whereas during eggs and spermatogenesis or at or near designing. As novo mutations underpinning a substantial part of which dominant genetic disease, which Find for it critical into comprehensive prenatal genetic diagnosis of. Which researchers demonstrated that could be ultra – deep sequencing, bioinformatics and statistical are genome-wide de novo mutations in the the growing fetus. You discovered 39 of the 44 baby de novo mutations, while it was a fetus.

Random entries

Other entries from category "venereology":